Voices for

CHANGE

2007 Annual Report
Be the **CHANGE** that you want to see in the world.

*Mahatma Gandhi*
The Leukemia & Lymphoma Society's 2007 Annual Report focuses on affecting change through exemplary action. We chose this theme because 2007 saw our organization on the move and creating changes that will advance our mission.

This year, the efforts of our volunteers and staff resulted in a significant milestone: For the first time, Society revenue broke the $300 million mark. With gross revenue of more than $317 million, we are now the third-largest voluntary health agency* in the United States. Thanks to the generosity of individuals, foundations, corporations and organizations this year, the Society funded more than 400 researchers and made more than 5.1 million patient contacts.

During the year, we also began to put into action changes that will lead to our North Star 2015 Vision, creating a world for patients that will allow them to experience the best possible outcomes for their specific blood cancer. For many, that will mean cures.

This year, we implemented a Co-Pay Assistance Program to help eligible blood cancer patients meet the costs of insurance premiums and co-pays.

The Society also launched a diversity initiative in an effort to recognize and respond more effectively to the increasingly varied needs of the communities we serve. As a first step, we conducted a study to identify areas of gender, race, culture and ethnicity that are underrepresented within the Society. This information will guide us in formulating strategies to take us toward a Society-wide, cultural transformation. It is an important change that will help us accomplish our goal of providing service to all blood cancer patients within 30 days of diagnosis.

These are the first of many new ways of doing business for the Society that will alter the healthcare landscape for our patients and their caregivers.

The 2007 Annual Report profiles three volunteers who, as activists in our advocacy program, work to impact public policy to help advance the Society's mission. Their spirit and ideals represent those of all our constituents who, in their own ways, live the changes we all wish to see.

* Total private support
Each spring, the Society brings a strong and dedicated force of people to Capitol Hill to speak with members of Congress about issues of importance to blood cancer patients. These include the need for increased government funding of biomedical research, collaborative public-private sector research efforts and patient protection legislation guaranteeing all healthcare consumers fundamental rights, such as the right to receive care in a clinical trial.
**Rich Beres** first became involved with the Society in 1988 when he lost his wife Jane to leukemia. Before her death, Jane was part of several research studies. She was committed to advancing science so other patients could benefit from her experience.

Ten years later, Rich heard about a new Society event, Light The Night® Walk, and he participated as a way of commemorating Jane and continuing to support her ideals. That led to his becoming a Society advocate, where he was instrumental in the passage of Wisconsin’s Cancer Patient Protection Act.

“I was never much of an advocate until I attended my first Society Mission Day. I was the only representative from Wisconsin and I felt my voice was heard throughout my day on the Hill. I have repeated the experience several times and am re-energized on each occasion. The feeling that I am making an impact is very gratifying. And I’m now comfortable being able to go to my local legislators’ offices to represent issues of importance to the cancer community.

Personally, I feel passionate about the work I’m doing. Jane was my life, my wife, mother to our three daughters and my best friend. I have been fortunate to marry a second time, to Jerilynne, a wonderful woman and mother who understands that I still, and always will, miss Jane. In fact, the decision to walk in Light The Night was a joint one, and Jerilynne is completely supportive of the Society’s mission.

To anyone who is thinking of becoming an advocate, I’d say our legislators are people just like you and me. They are also our employees. They have power, but they need to listen to us. And I have seen firsthand what the power of one can do through my role in getting the clinical trials legislation passed. Every American has a voice in what happens in our country—use your voice!”

**Rich Beres**

A husband who speaks on the Hill
At one time, few if any children with acute lymphocytic leukemia survived. Fortunately, advances in treatment now make cures possible for 87 percent of children with this disease. But with this good news come new challenges, such as the long-term effects of treatment. Physical growth or a child’s ability to learn may be impaired. It is important that these problems be identified early and that parents seek professional advice about the need to have children’s learning skills assessed.
**Liz Salguero** is the mother of an 8-year-old son, Carlos, who was diagnosed with acute lymphocytic leukemia (ALL). During his two-and-a-half years of treatment, she learned a great deal about pediatric cancer and the late effects of treatment. As a Society advocate, Liz was instrumental in getting legislation passed requiring insurance companies in her state to cover baseline neurocognitive testing for all pediatric cancer patients.

“I first became involved with the Society through a support group they offered to parents and siblings of children with cancer. Later, I shared my experiences with families of newly diagnosed children through the Society’s First Connection program.

Serving as chair of the Connecticut Chapter’s Patient Services Committee led to my role as an advocate. Our first project: Get a bill passed in the state legislature requiring insurance coverage of baseline cognitive testing for all children who have undergone cancer treatment. Our family had to bear the cost of this very expensive testing, so it was an issue close to my heart.

The most important ingredient for advocacy is passion; that drives most of what we do. Speaking before the legislature is intimidating, but I was certain our position was right, and we didn’t back down. We thought it would take years to accomplish our goal, and we were exhilarated when it took only one legislative session!

We are only beginning to understand the long-lasting cognitive effects of cancer treatment. It will be important to raise awareness of the ongoing needs of survivors for years to come; to obtain funding to educate families about the long-term effects of treatment; and to advocate for coverage of associated conditions.”

---

**Liz Salguero**

A mother whose passion drives her advocacy

---

The Leukemia & Lymphoma Society
**U.S. Rep. Doris Matsui (D-CA)** met her husband, former U.S. Rep. Robert Matsui, while attending the University of California, Berkeley. She has had an enduring political career at a Washington law firm and as an official in the Clinton White House, where she also chaired a group appointed by the president to strengthen relations between the federal government and the nonprofit community.

On January 2, 2005, just two months after celebrating their 38th wedding anniversary, Robert died of complications from myelodysplastic syndrome (MDS), a rare blood disorder originating in the bone marrow. In the special election held later that year to fill her late husband’s congressional district seat, Doris was elected to the position she still holds today.

“I believe that as a Member of Congress, I have a moral obligation to try and create a better, healthier America. I was elected to use the resources available through local, state and federal government to fulfill this responsibility.

Cancer is one of the most difficult healthcare challenges of the 21st century, affecting nearly everyone in our country. I have been committed to this cause since my earliest days in public service. But since my husband died of MDS, I met many blood cancer patients, and the more I learned, the more I wanted to advocate for this cause.

The most important thing that government can do to support people battling cancer is to fund medical researchers developing cures and therapies. I have always supported robust funding levels for the National Institutes of Health and the National Cancer Institute, and will continue to do so. The more cancer research government funds and follows through on, the more lives will be saved.

At the end of the day, I’m just like every other American. I worry about the health and well being of my loved ones. When I look back on Bob’s battle with MDS and think how much more he could have accomplished in his life, it motivates me to find ways to address America’s key concerns. At the same time, I look at my grandchildren and think about the kind of America we are going to pass down to future generations. These thoughts guide my priorities each day.”
The need for advocacy has never been greater: Between 1998 and 2005, the National Cancer Institute experienced robust funding growth, widely correlated with an unprecedented decrease in cancer-related deaths in the United States for two straight years, despite an aging and growing population. Many researchers believe the decline was due to increased prevention, early detection and new treatments that were tested in clinical trials.

But in 2006, federal funding began to slow. By 2007, it was flat at $4.79 billion, and projections for 2008 signal a downturn. There is justifiable concern in the medical and scientific communities about the impact of these trends at a time when the opportunities to advance cancer cures have never been so promising. The expectation is that decreased levels of funding will result in a loss of momentum that will be costly to recover; and fewer clinical trial options, fewer new therapies and fewer survivors.
Fiscal Year 2007 Society Highlights

Changing Patient Outcomes…

Through Research

The Society’s research programs support basic, translational and clinical research that focuses on the cause, treatment and prevention of blood cancers.

The Specialized Center of Research (SCOR) Program

Four new SCOR grants were awarded in fiscal year 2007, and a total of 22 outstanding, collaborative, multi-disciplinary studies are running at full throttle. The following are examples of significant progress being contributed through SCOR grantees:

- John Byrd, M.D., The Ohio State University, and his SCOR team have made several important breakthroughs in the past year in the treatment of chronic lymphocytic leukemia (CLL):
  - In two clinical studies, Rituxan®, the antibody drug used successfully to treat many B-cell lymphoma patients, was found to be safe and effective as a CLL treatment when administered with the drug fludarabine.
  - A new antibody drug proved effective against CLL cells in test tube and early animal tests.
  - A drug originally developed to prevent organ transplant rejection was also found to kill CLL cells.

- Helen Heslop, M.D., Baylor College of Medicine, and her SCOR team are developing immunotherapies to treat Hodgkin lymphoma:
  - Their new research builds on previous, Society-funded work, which showed that specialized immune cells (cytotoxic T lymphocytes) can be engineered and used with vaccines to treat or even prevent Epstein-Barr virus (EBV)-related lymphomas in immunocompromised patients.
  - Now, the team is using bioengineering techniques to develop a more universal anti-lymphoma therapy that is proving effective in the laboratory and is likely to help an even larger number of lymphoma patients.
  - Similar strategies are likely to help patients with other blood cancers.

Research breaking new ground

The Society funds other research aimed at understanding cancer stem cells, increasingly appreciated as the root of some blood cancers and the possible source of relapses. The Society also supports the discovery of cancer-causing molecular abnormalities, including very large genetic abnormalities that were unrecognized until just this year, and “epigenetic” abnormalities that can cause cancer without changing the genetic code at all.

These sea-change understandings may make possible the development of new “targeted” therapies that effectively kill cancer cells more specifically than today’s standard treatments and with fewer side-effects. Small chemicals and antibodies are in this new drug pipeline, and targeted immunotherapies are being developed to help patients’ own immune systems better fight their cancers.
An added focus on survivorship issues and late effects

- Standard treatments for blood cancer and solid tumor cancer patients can cause adverse long-term side-effects, including a range of secondary cancers. Through a new initiative announced in 2007, the Society is seeking grant applications from researchers whose work addresses the health issues of cancer survivors. New awards in this area will extend existing Society-funded research to understand which treatments will be most effective for each patient while carrying the lowest risk of late and long-term side-effects.

Elly Barry, M.D., Dana-Farber Cancer Institute, a Society Special Fellow in Clinical Research, is working to reduce potential heart abnormalities among children following leukemia treatment. These life-threatening side-effects can be caused by commonly used anthracycline drugs and the iron complexes that form once they are administered. Dr. Barry is studying whether common changes in genes that process iron might increase the risk of heart complications. If so, genetic tests could identify at-risk patients so that alternative treatments could be employed.

...Through Patient Services

As more children survive childhood cancer, there is a need to focus on the long-term cognitive effects of their treatment. These “late effects” can result in learning issues that affect academic performance and require special resources. The Society is the leading organization providing resources of staff and educational programs to combat this growing problem.

The Society’s Welcome Back: Facilitating the Return to School for Children with Cancer program educates school nurses and other personnel about the needs of these children during and after their return to school. A grant from Regence BlueCross BlueShield of Oregon this year gave the program extra clout over a four-state area. Financial support was also provided by the Lance Armstrong Foundation.

Additional education on issues facing pediatric cancer patients and their families is provided through Focus on Childhood Cancer, an extensive series of Society telephone education programs that is archived on our Web site, www.LLS.org. Two new programs were added to the series in fiscal year 2007: How Childhood Cancer Touches the Entire Family and Education Challenges After Treatment: Middle School Through College.

...Through Advocacy

The Society’s Patient Advocates Network, more than 16,000 volunteers strong and growing, has affected a range of public policies that will enhance the search for cures and improve the quality of education, access and treatment of blood cancer patients:

- As of fiscal year 2007, advocates have secured a total of $28 million in blood cancer research funding from the U.S. Department of Defense.

- In 2007, the five-year total that Society advocates have secured for blood cancer patient education from the federal Centers for Disease Control and Prevention reached nearly $25 million. As one of the organizations that has received grants from these funds, the Society has inaugurated outreach programs to elderly and underserved blood cancer patients.

- Campaigns to guarantee insurance coverage for patients enrolled in cancer clinical trials were launched in New York and Pennsylvania, modeled on the passage of legislation in California and Wisconsin.
Fiscal Year 2007 Fundraising Highlights

Changing Patient Outcomes...

...Through Fundraising Campaigns

**Team In Training® (TNT),** the world’s largest endurance sports training program, continued its amazing growth, raising more than $125 million in fiscal year 2007 – 10 percent higher than the previous year. Since it started in 1988, TNT has trained 340,000 people for marathons, half marathons, triathlons and 100-mile cycling events. The campaign has raised more than $800 million to help find cures.

**Light The Night Walk,** the nation’s night to pay tribute and bring hope to people battling cancer, exceeded its goal this year, raising nearly $35 million to help advance the Society’s mission. Thousands of participants in 240 communities walked and raised funds, lighting the night with hope.

**School & Youth™ Programs** also exceeded budget this year: Ten million students in 21,000 schools raised $18.5 million, demonstrating the power of young people to change the world!

...Through Donor Development

On behalf of patients and their families, the Society expresses its gratitude to the very special donors whose commitments totaled $31.4 million in fiscal year 2007. This figure included $4.9 million in bequests from individuals who had the foresight to include the Society in their estate plan. We exceeded our goal and are inspired to seek increased participation in fiscal year 2008. We are proud that 100 percent of donor-restricted gifts for research, patient services and advocacy support the Society’s mission.
Research Grants*

Specialized Center of Research 1
Jerry Adams, PhD | 2007 | The Walter and Eliza Hall Institute of Medical Research
Frederick Alt, PhD | 2007 | CBRI Institute of Biomedical Research, Inc.
Jon Aster, MD, PhD | 2008 | Brigham and Women’s Hospital
Irwin Bernstein, MD | 2008 1 | Fred Hutchinson Cancer Research Center
John Bushweller, PhD | 2005 1 | University of Virginia
John Byrd, MD | 2006 1 | The Ohio State University
Riccardo Dalla-Favera, MD | 2004 1 | Columbia University
Brian Druker, MD | 2006 1 | Oregon Health & Science University Cancer Institute
Carolyn Felix, MD | 2007 1 | The Children’s Hospital of Philadelphia
Anthony Green, MD, PhD | 2007 | University of Cambridge
James Griffin, MD | 2006 1 | Dana-Farber Cancer Institute
Helen Heslop, MD | 2004 | Baylor College of Medicine
Carl June, MD | 2007 1 | University of Pennsylvania
Thomas Kipps, MD, PhD | 2006 | University of California, San Diego
Larry Kwak, MD, PhD | 2008 | The University of Texas
Ronald Levy, MD | 2006 10 | Stanford University
Jonathan Licht, MD | 2008 | Northwestern University
Scott Lowe, PhD | 2004 1 | Cold Spring Harbor Laboratory
Tak Mak, PhD | 2005 1 | University of Toronto
Stephen Nimer, MD | 2007 | Memorial Sloan-Kettering Cancer Center
Michael Thirman, MD | 2007 11 | University of Chicago
Cheryl L.Willman, MD | 2006 | University of New Mexico
Chris Counter, PhD | 2003 | Duke University Medical Center
John Crispino, PhD | 2006 | Northwestern University
Blossom Damania, PhD | 2006 | University of North Carolina at Chapel Hill
Abby Dernburg, PhD | 2007 | University of California, Berkeley
J. Alan Diehl, PhD | 2007 | University of Pennsylvania
Wei Du, PhD | 2004 | University of Chicago
Michael Eck, MD, PhD | 2003 | Dana-Farber Cancer Institute
Christine Eischen, PhD | 2005 | Vanderbilt University Medical Center
Michael Ferrar, PhD | 2008 | University of Minnesota, Twin Cities
Xin-Hua Feng, PhD | 2004 | Baylor College of Medicine
Adolfo Ferrando, MD, PhD | 2008 | Columbia University
H. Leighton Grimes, PhD | 2006 | Cincinnati Children’s Hospital Medical Center
Xi He, PhD | 2006 | Children’s Hospital Boston
Jin Jiang, PhD | 2004 14 | The University of Texas
Craig Jordan, PhD | 2004 | University of Rochester
Scott Keeney, PhD | 2006 | Memorial Sloan-Kettering Cancer Center
Michelle Kelliher, PhD | 2004 15 | University of Massachusetts Medical School
William Kerr, PhD | 2003 16 | University of South Florida
Scott Kogan, MD | 2005 | University of California, San Francisco
Anthony Koleske, PhD | 2003 | Yale University
Motanari Kondo, MD, PhD | 2008 | Duke University Medical Center
Stephen Kron, MD, PhD | 2003 | University of Chicago
Matthew Krummel, PhD | 2006 | University of California, San Francisco
Sang Eun Lee, PhD | 2008 | The University of Texas
Gustavo Leone, PhD | 2005 | The Ohio State University
Willa Li, PhD | 2008 | University of Rochester
Shaoguang Li, MD, PhD | 2008 | Jackson Laboratory
Xin Lin, PhD | 2005 | The University of Texas
Wen-Chin Lin, MD, PhD | 2007 | University of Alabama at Birmingham
Hiten Madhani, MD, PhD | 2006 | University of California, San Francisco
Andreas Matsoukas, PhD | 2003 | Northwestern University
Ari Melnick, MD | 2007 | Albert Einstein College of Medicine
Danesh Mozayed, PhD | 2006 | Harvard Medical School
George Miosos, PhD | 2005 | Biomedical Sciences Research Center
Duojia Pan, PhD | 2007 | Johns Hopkins University
Danilo Perrotti, MD, PhD | 2008 | The Ohio State University
Christoph Plass, PhD | 2003 | The Ohio State University
Ishwar Radhakrishnan, PhD | 2005 | Northwestern University
Dale Ramsden, PhD | 2007 | University of North Carolina at Chapel Hill
Linda Ries, MD | 2006 17 | Johns Hopkins University
Tannisha Reya, PhD | 2008 | Duke University Medical Center
Theodora Ross, MD, PhD | 2006 | University of Michigan
Guy Sauvageau, MD, PhD | 2003 | University of Montreal
Stephen Schoenberner, PhD | 2006 | La Jolla Institute for Allergy and Immunology
Ralph Scully, MD, PhD | 2006 | Beth Israel Deaconess Medical Center
David Sharp, PhD | 2005 | Albert Einstein College of Medicine
Ali Shilatifard, PhD | 2002 | Saint Louis University School of Medicine
Peter Sciniski, MD, PhD | 2006 | Dana-Farber Cancer Institute
Zhou Songyang, PhD | 2007 | Baylor College of Medicine
Milan Stojanovic, PhD | 2008 | Columbia University
Reshma Taneja, PhD | 2003 | Mount Sinai School of Medicine
Michael Tessler, MD | 2004 18 | University of California, Los Angeles

The Leukemia & Lymphoma Society 13

---

1 The year displayed after each grant represents the first fiscal year of grant activity.
2 The Specialized Center of Research Program is funded in part by the Peter and Elinor Smith, Elaine Smith and Imagine a Cure for Leukemia.
3 Dr. John Byrd is funded in part by Doug and Phyllis Smith, Elaine Smith and Imagine a Cure for Leukemia.
4 Dr. Riccardo Dalla-Favera is funded in part by Lesley Goldwasser and Jonathan Pluzik, Joseph S. and Diane H. Steinberg, Deborah and Jeff Briggs, Tracy and Frank Colin, James F. Egan, James and Karen Finkel, Paul and Susan Friedman, Jonathan and Joanne Lovince, Tom Marano, Jeffrey and Katina Mayer, The Edward Mitten Foundation, Michael and Ela Nirenberg and Family, and Daniel and Carol Spina.
5 Dr. Brian Druker is funded in part by Imagine a Cure for Leukemia.
6 Dr. Geraldine Fox is funded in part by the Samuel P. Mandell Foundation.
7 Dr. James Griffin is funded in part by the Virginia Sheildon Jerome Foundation, Frederic M. Adler and Susan and Rick Theiler – Cure Kids’ Cancer Golf.
8 Dr. Carl June is funded in part by Lisa and Brian Bee.
9 Dr. Christoph Plass is funded in part by The Josephine C. Sarfiggio Memorial Fund.
10 Dr. Scott Lowe is funded in part by Mr. and Mrs. Anthony Campbell and The Atsulis Foundation/Richardson Memorial.
11 Dr. Tak Mak is funded in part by Dr. and Mrs. Ronald Levy in Support of Cancer Research.
12 Dr. Michael Thirman is funded in part by the Alverin J. Caswell Foundation, the Albert Einstein College of Medicine Foundation, the Harold D. and Hazel C. Wright Foundation.
13 Dr. Jin Jiang is fully funded by the St. Valentine’s Day Luncheon and Style Show.
### Research Grants (continued)

<table>
<thead>
<tr>
<th>Career Development Program: Scholars in Clinical Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ravi Bhatia, MD</td>
</tr>
<tr>
<td>City of Hope National Medical Center</td>
</tr>
<tr>
<td>Catherine Bollard, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Ivan Borrello, MD</td>
</tr>
<tr>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Martin Carroll, MD</td>
</tr>
<tr>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>Kenneth Cooke, MD</td>
</tr>
<tr>
<td>Case Western Reserve University</td>
</tr>
<tr>
<td>Ephraim Fuchs, MD</td>
</tr>
<tr>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Zhihe Li, MD, PhD</td>
</tr>
<tr>
<td>University of Connecticut</td>
</tr>
<tr>
<td>Mignon Loh, MD</td>
</tr>
<tr>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Owen O’Connor, MD, PhD</td>
</tr>
<tr>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td>Robert Orlowski, MD, PhD</td>
</tr>
<tr>
<td>University of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>David Rizzieri, MD</td>
</tr>
<tr>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Warren Shlomchik, MD</td>
</tr>
<tr>
<td>Yale University</td>
</tr>
<tr>
<td>Jeffrey Taub, MD</td>
</tr>
<tr>
<td>Wayne State University</td>
</tr>
<tr>
<td>Joseph Wiemels, PhD</td>
</tr>
<tr>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>William Wierda, MD, PhD</td>
</tr>
<tr>
<td>The University of Texas</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Career Development Program: Special Fellows</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laurie Ailles, PhD</td>
</tr>
<tr>
<td>Stanford University</td>
</tr>
<tr>
<td>Jennifer Antonchuk, PhD</td>
</tr>
<tr>
<td>University of Edinburgh</td>
</tr>
<tr>
<td>Toshiyuki Araki, PhD</td>
</tr>
<tr>
<td>University of Toronto</td>
</tr>
<tr>
<td>Claire Attwood, PhD</td>
</tr>
<tr>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td>Itai Ben-Porath, PhD</td>
</tr>
<tr>
<td>Whitehead Institute for Biomedical Research</td>
</tr>
<tr>
<td>Marzenna Błonska, PhD</td>
</tr>
<tr>
<td>The University of Texas</td>
</tr>
<tr>
<td>Klara Brikiranova, PhD</td>
</tr>
<tr>
<td>The University of Montana – Missoula</td>
</tr>
<tr>
<td>Katja Bruckner, PhD</td>
</tr>
<tr>
<td>Harvard Medical School</td>
</tr>
<tr>
<td>Julie Camman, PhD</td>
</tr>
<tr>
<td>Ludwig Institute for Cancer Research</td>
</tr>
<tr>
<td>Kate Carroll, PhD</td>
</tr>
<tr>
<td>University of Michigan</td>
</tr>
<tr>
<td>Andrew Carter, PhD</td>
</tr>
<tr>
<td>Princeton University</td>
</tr>
<tr>
<td>Rafal Ciosik, PhD</td>
</tr>
<tr>
<td>Novartis Forschungsstiftung</td>
</tr>
<tr>
<td>Sean Conner, PhD</td>
</tr>
<tr>
<td>University of Minnesota, Twin Cities</td>
</tr>
<tr>
<td>Zhong Deng, PhD</td>
</tr>
<tr>
<td>Wistar Institute</td>
</tr>
<tr>
<td>Takeshi Egawa, MD, PhD</td>
</tr>
<tr>
<td>New York University School of Medicine</td>
</tr>
<tr>
<td>Hui Feng, PhD</td>
</tr>
<tr>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Pinghui Feng, PhD</td>
</tr>
<tr>
<td>The University of Texas</td>
</tr>
<tr>
<td>Josephine Ferreeman, PhD</td>
</tr>
<tr>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Daniel Foltz, PhD</td>
</tr>
<tr>
<td>Ludwig Institute for Cancer Research</td>
</tr>
<tr>
<td>Casey Fox, PhD</td>
</tr>
<tr>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>Xingsheng Gao, PhD</td>
</tr>
<tr>
<td>The University of Texas</td>
</tr>
<tr>
<td>Julie Gates, PhD</td>
</tr>
<tr>
<td>Bucknell University</td>
</tr>
<tr>
<td>Sourav Ghosh, PhD</td>
</tr>
<tr>
<td>Salk Institute for Biological Studies</td>
</tr>
<tr>
<td>Florent Ginhoux, PhD</td>
</tr>
<tr>
<td>Mount Sinai School of Medicine</td>
</tr>
<tr>
<td>Wendy Gordon, PhD</td>
</tr>
<tr>
<td>Brigham and Women’s Hospital</td>
</tr>
<tr>
<td>Monica Gostissa, PhD</td>
</tr>
<tr>
<td>CBR Institute of Biomedical Research, Inc.</td>
</tr>
<tr>
<td>Alla Grishok, PhD</td>
</tr>
<tr>
<td>Columbia University</td>
</tr>
<tr>
<td>David Guertin, PhD</td>
</tr>
<tr>
<td>Whitehead Institute for Biomedical Research</td>
</tr>
<tr>
<td>Bei Chu Guo, PhD</td>
</tr>
<tr>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>Karen Haas, PhD</td>
</tr>
<tr>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Toshiyuki Araki, MD</td>
</tr>
<tr>
<td>University of Chicago</td>
</tr>
<tr>
<td>Cheng-Fu Kao, PhD</td>
</tr>
<tr>
<td>Ludwig Institute for Cancer Research</td>
</tr>
<tr>
<td>Kieran Harvey, PhD</td>
</tr>
<tr>
<td>Peter MacCallum Cancer Institute</td>
</tr>
<tr>
<td>Beate Heissig, MD, PhD</td>
</tr>
<tr>
<td>Nintendo University</td>
</tr>
<tr>
<td>Ian Henderson, PhD</td>
</tr>
<tr>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>Gilles Hickson, PhD</td>
</tr>
<tr>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Amy Holdorf, PhD</td>
</tr>
<tr>
<td>Mount Sinai School of Medicine</td>
</tr>
<tr>
<td>Ke Hu, PhD</td>
</tr>
<tr>
<td>Indiana University</td>
</tr>
<tr>
<td>Jing Huang, PhD</td>
</tr>
<tr>
<td>Wistar Institute</td>
</tr>
<tr>
<td>Tara Huber, PhD</td>
</tr>
<tr>
<td>Genome Institute of Singapore</td>
</tr>
<tr>
<td>Matthias Hundt, MD</td>
</tr>
<tr>
<td>La Jolla Institute for Allergy and Immunology</td>
</tr>
<tr>
<td>Kristen Hurow-Neely, PhD</td>
</tr>
<tr>
<td>Brigham and Women’s Hospital</td>
</tr>
<tr>
<td>Miko Iijima, PhD</td>
</tr>
<tr>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Julie Jameson, PhD</td>
</tr>
<tr>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Edith Jannsen, PhD</td>
</tr>
<tr>
<td>La Jolla Institute for Allergy and Immunology</td>
</tr>
<tr>
<td>Sue Jaspersen, PhD</td>
</tr>
<tr>
<td>Stowers Institute for Medical Research</td>
</tr>
<tr>
<td>Przemysław Juszczynski, MD, PhD</td>
</tr>
<tr>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Axel Kallies, PhD</td>
</tr>
<tr>
<td>The Walter and Eliza Hall Institute of Medical Research</td>
</tr>
<tr>
<td>Cheng-Fu Kao, PhD</td>
</tr>
<tr>
<td>Academia Sinica</td>
</tr>
<tr>
<td>Karen Kee Shan, PhD</td>
</tr>
<tr>
<td>University of Pennsylvania</td>
</tr>
</tbody>
</table>

---

13 Dr. Michelle Tetzell is fully funded by the Remlikid Family Foundation.
14 Dr. William Kerr is fully funded by the Newman Foundation.
15 Dr. Linda Rosar is funded in part by the Cora and John H. Davis Foundation.
Dr. Yinghui Mao is fully funded by Angelo Defillipos and friends.

Scripps Research Institute
Jung-Hyun Min, PhD | 2005
Brigham and Women's Hospital
Thomas Mercher, PhD | 2006
Columbia University
Francene Lemoine, PhD | 2007
Duke University Medical Center
Anthony Leung, PhD | 2008
Massachusetts Institute of Technology
Jidong Liu, PhD | 2006
Memorial Sloan-Kettering Cancer Center
Yunmei Ma, PhD | 2007
Johns Hopkins University
Brendan Manning, PhD | 2005
Harvard School of Public Health
Yinghui Mao, PhD | 2005
Columbia University
Thomas Mercher, PhD | 2006
Brigham and Women's Hospital
Jung-Hyun Min, PhD | 2005
Memorial Sloan-Kettering Cancer Center
Nam-Sung Moon, PhD | 2008
Massachusetts General Hospital
Raul Mostoslavsky, MD, PhD | 2005
Massachusetts General Hospital Cancer Center
Leta Nusz, PhD | 2008
Duke University Medical Center
Sean O'Rourke, PhD | 2006
University of Oregon
Ryoma Ohi, PhD | 2005
Harvard Medical School
Amir Oryan (Orian), MD, PhD | 2005
Technion, Israel Institute of Technology
Hyewon Phee, PhD | 2007
University of California, San Francisco
Kathrin Plass, PhD | 2005
University of California, Los Angeles
Supriya Prasanth, PhD | 2006
University of Illinois at Champaign-Urbana
Philippe Prochasson, PhD | 2007
MRC Clinical Sciences Centre
Youjun Qian, PhD | 2007
Cleveland Clinic
Jan Qu, PhD | 2005
University of California, San Francisco
John Randell, PhD | 2007
Massachusetts Institute of Technology
Attila Remenyi, PhD | 2007
University of California, San Francisco
Andrey Reyasaki, PhD | 2008
University of California, Berkeley
Lauren Richie-Ehrlich, PhD | 2007
Stanford University
Monideepa Roy, PhD | 2008
Brigham and Women's Hospital
Hyung Ryoo, PhD | 2006
New York University
Shireen Saleque, PhD | 2004
Children's Hospital Boston
Adrian Salic, PhD | 2006
Harvard Medical School
Tomoyuki Sawado, PhD | 2005
Fred Hutchinson Cancer Research Center
Yongchong Song, PhD | 2006
University of Illinois at Champaign-Urbana
Eric Spierings, PhD | 2005
Leiden University Medical Center
Walter Steiner, PhD | 2005
Niagara University
Angela Stoddart, PhD | 2005
University of Chicago
Travis Stracker, PhD | 2008
Memorial Sloan-Kettering Cancer Center
Gergely Szakacs, MD, PhD | 2007
Biological Research Center, Hungarian Academy of Sciences
Vinyi Tergaonkar, PhD | 2005
Salk Institute for Biological Studies
Giovanni Tonton, MD, PhD | 2007
Dana-Farber Cancer Institute
Ivan Tosiopoulos, MD, PhD | 2008
IRIC – Institut de Recherche en Immunovirologie et en Cancérologie
Emily Traemel, PhD | 2007
Massachusetts General Hospital
Takehiko Utsui, PhD | 2005
Memorial Sloan-Kettering Cancer Center
Lidia Vasilieva, PhD | 2008
Harvard Medical School
Ramiro Verdun, PhD | 2007
Salk Institute for Biological Studies
Carl Walkley, PhD | 2007
Dana-Farber Cancer Institute
Roland Walter, MD, PhD | 2007
Fred Hutchinson Cancer Research Center
Jing Wang, MD, PhD | 2006
Children's Hospital Boston
Dong Wang, PhD | 2008
Stanford University
Wenqi Wei, PhD | 2006
Children's Hospital Boston
Zhaojun Wu, MD, PhD | 2005
University of Wisconsin at Madison
Ning Wu, PhD | 2007
Baylor College of Medicine
Tingting Yao, PhD | 2008
Stanford University
Katarzyna Yarosz, PhD | 2008
Scripps Research Institute
Akihiko Yokochi, PhD | 2006
University of Chicago
Akihiko Yokoyama, PhD | 2006
Flordia State University
Jianbo Yue, PhD | 2006
Dana-Farber Cancer Institute
Dan Vogl, MD | 2008
University of Pennsylvania

Career Development Program: Special Fellows in Clinical Research
Philippe Armand, MD, PhD | 2008
Dana-Farber Cancer Institute
Billy Barry, MD | 2007
Dana-Farber Cancer Institute
Mari Dallas, MD | 2008
Fred Hutchinson Cancer Research Center
Jeffrey Davies, MD, PhD | 2007
Dana-Farber Cancer Institute
Alice Fan, MD | 2007
Stanford University
Noelle Frey, MD | 2008
University of Pennsylvania
Robert Jeng, MD | 2008
Memorial Sloan-Kettering Cancer Center
Alexander Perl, MD | 2007
University of Pennsylvania
Loredana Ruggiero, MD, PhD | 2007
Université de Perugia

Career Development Program: Fellows
David Aiello, PhD | 2005
Merrick University
Christopher Balal, MD | 2007
Harvard Medical School
Michael Bassik, PhD | 2007
University of California, San Francisco
Linda Baughn, PhD | 2007
Weill Medical College of Cornell University
Michael Begley, PhD | 2008
Beth Israel Deaconess Medical Center
Marie Bleakley, MD | 2006
Dana-Farber Cancer Institute

Dr. Yinghui Mao is fully funded by Angela Defillipos and friends.

Dr. Amir Oryan is fully funded by Pamela B. Katten Memorial Leukemia Research Foundation.

Dr. Roland Walter is funded in part by the Dan Glaston Memorial Research Fund.

Dr. Hans-Guido Wendel is funded in part by Senator Fisheries and the New York State Department of Health.

Dr. Jeffrey Davies is funded in part by Steve and Lisa Boon.

Dr. Alexander Perl is fully funded by the Douglas Kroll Research Program and Margaret Rado.

Dr. Marie Bleakley is funded in part by Lisa and Brian Biss.

The Leukemia & Lymphoma Society
Tatiana Bondar, PhD | 2007 Sc
Yale University
Deirdre Buckley, PhD | 2004 Sc
Cold Spring Harbor Laboratory
Gerd Bungartz, PhD | 2008 Sc
University of Pennsylvania
Jing Chen, PhD | 2005 Em
Emory University
Danica Chen, PhD | 2006 Ms
Massachusetts Institute of Technology
Jihua Chen, MD, PhD | 2006 Dn
Dana-Farber Cancer Institute
Stella Chou, MD | 2007 Ch
The Children’s Hospital of Philadelphia
Dipanjan Chowdhury, PhD | 2005 Cb
CBR Institute of Biomedical Research, Inc.
Sergei Chukov, PhD | 2007 Cb
CBR Institute of Biomedical Research, Inc.
Maria Ciofani, Hon. B. Sc. | 2008 Yn
New York University
Pasquale Cirone, PhD | 2008 Yn
Yale University
Alexandre Costa, PhD | 2007 St
Stanford University
Louise D’Cruz, PhD | 2008 Uo
University of California, San Diego
Warren D’Souza, PhD | 2006 Uo
University of California, San Diego
Abhishek Datta, PhD | 2007 Cb
CBR Institute of Biomedical Research, Inc.
Michael Davis, PhD | 2008 Fh
Fred Hutchinson Cancer Research Center
Ludovic Deriano, PhD | 2008 Uo
University of California, San Francisco
Tracy Diamond, PhD | 2006 Uo
University of Pennsylvania
Jinyan Du, PhD | 2007 Df
Dana-Farber Cancer Institute
Sheryl Elkin, PhD | 2007 Ms
Massachusetts Institute of Technology
Nicholas Endres, PhD | 2008 Uo
University of California, Berkeley
Koija Eppert, PhD | 2008 Uo
University of Toronto
Sylvia Fischer, PhD | 2005 Ms
Massachusetts General Hospital
James Forrest, PhD | 2005 Em
Emory University
Kyriaki Galani, PhD | 2008 Ms
Massachusetts Institute of Technology
Neil Ganem, PhD | 2008 Df
Dana-Farber Cancer Institute
Benjamin Gewurz, MD, PhD | 2008 Br
Brigham and Women’s Hospital
Danna Hargett, PhD | 2008 Pe
Princeton University
Jin He, MD, PhD | 2008 Uo
University of North Carolina at Chapel Hill
Kiersten Henderson, PhD | 2008 Fh
Fred Hutchinson Cancer Research Center
Eun-Jin Hong, PhD | 2006 Ms
Harvard Medical School
Daniel Hostetter, PhD | 2006 Uo
University of California, San Francisco
Jian Huang, MD, PhD | 2008 St
Stanford University
Jonathan Irish, PhD | 2006 Gr
Stanford University
Hao Jiang, PhD | 2007 Rf
Rutgers University
Kristen Johnson, PhD | 2006 Uo
University of Chicago
David Kashatus, PhD | 2008 Df
Duke University Medical Center
Karen Keeshan, PhD | 2005 Ms
University of Pennsylvania
Valery Krizhanovsky, PhD | 2007 Sc
Cold Spring Harbor Laboratory
Marc Kvarsakul, PhD | 2006 Th
The Walter and Eliza Hall Institute of Medical Research
Sanny Lamouille, PhD | 2007 Uo
University of California, San Francisco
Mark Lanasa, MD, PhD | 2007 Df
Duke University Medical Center
Nicolas Larmion, PhD | 2007 Ms
University of Arizona
Erica Larcham, PhD | 2005 Ms
Harvard Medical School
Xiaoling Li, PhD | 2005 Ms
Massachusetts Institute of Technology
Xiaochen Liang, PhD | 2006 Em
Emory University
Chengyu Liang, MD, PhD | 2008 Ms
Harvard Medical School
Chinten Lim, PhD | 2005 Sr
Scripps Research Institute
Ling Liu, PhD | 2008 St
Stanford University
Miao-Chia Lo, PhD | 2008 Sr
Scripps Research Institute
Simonne Longerich, PhD | 2008 Ms
Yale University
Michelle Longworth, PhD | 2007 Ms
Massachusetts General Hospital
Li-Fan Lu, PhD | 2008 Ms
University of Washington
Edward Luk, PhD | 2006 Nio
National Institutes of Health
Julian Lum, PhD | 2005 Uo
University of Pennsylvania
Matthias Lutolf, PhD | 2007 St
Stanford University
Xiaoju Ma, PhD | 2007 Ms
Harvard Medical School
Eugene Maskey, PhD | 2005 Ms
Harvard University
Aron Marquitz, PhD | 2008 Uo
University of North Carolina at Chapel Hill
Vanessa Mardren, PhD | 2005 Pm
Peter MacCallum Cancer Centre
Carla Martin, PhD | 2006 Ms
University of California, San Francisco
Sebastiana Mejting, PhD | 2005 Ms
University of California, San Francisco
Savroula Mili, PhD | 2006 Ms
University of Virginia
Alexandre Morozov, PhD | 2006 Gr
Rutgers University
Tammy Morrish, PhD | 2007 Ms
Johns Hopkins University
Jing Pan, PhD | 2007 Ms
Memorial Sloan-Kettering Cancer Center
Lisa Postow, PhD | 2006 Ms
Rockefeller University
Martin Prlic, PhD | 2006 Ms
University of Washington
Thomas Pucadyil, PhD | 2008 Sr
Scripps Research Institute
Miles Pulfall, PhD | 2007 Ms
University of California, San Francisco
Bin Qian, PhD | 2006 Ms
University of Washington
Priyamvada Rai, PhD | 2006 Ms
Whitehead Institute for Biomedical Research
Anand Ranjan, PhD | 2008 Ms
National Cancer Institute
Lily Remsing Rix, PhD | 2005 Ms
Center for Molecular Medicine
Stefan Riedl, PhD | 2005 Ms
Blumham Institute
Davide Robbiani, MD, PhD | 2007 Ms
Rockefeller University
Edward Rogers, PhD | 2008 Ms
University of North Carolina at Chapel Hill
Karen Sachs, PhD | 2007 Ms
Stanford University
Stefanie Sarantopoulos, MD, PhD | 2006 Df
Dana-Farber Cancer Institute
Bernie Satin, PhD | 2007 Ms
Stanford University
Gary Shapiro, PhD | 2005 Ms
University of California, San Diego
Wei-Jong Shia, PhD | 2008 Sr
Scripps Research Institute
Erika Shor, PhD | 2007 Gr
University of Wisconsin at Madison
Rachael Siegel, PhD | 2008 Ms
Columbia University
Jonathan Snow, PhD | 2006 Ms
Children’s Hospital Boston
Erinn Soucie, PhD | 2006 Ms
Center National de la Recherche Scientifique
Matthew Strout, MD, PhD | 2008 Yn
Yale University
Jason Tanny, PhD | 2006 Ms
University of Montreal
Vera Tarakanova, PhD | 2006 Ms
Washington University
Ewan Taylor, PhD | 2006 Sr
Scripps Research Institute

35 Dr. Tatiana Bondar is fully funded by the Gertrude B. Elion Research Fund.
36 Dr. Jonathan Irish is funded in part by Gregory and Michelle Becker.
37 Dr. Alexandre Morozov is fully funded by the Lehman Brothers Foundation.
38 Dr. Erika Shor is fully funded by the Greater Milwaukee Foundation’s Elsa Schoenbach Medical Research Fund.
56 Dr. Scott Kaufmann is funded in part by the Mayo Clinic and Foundation.

57 Dr. Robert Orlowski is funded in part by the Mayo Clinic and Foundation.

60 Dr. Steven Grant is fully funded by the Peter Burg Memorial Research Fund.

61 Dr. Joseph Tuscano is funded in part by Dana and Charles Schott Foundation and Ironman for Miracles.

62 Dr. David Williams is funded in part by The Marge & Lynne accessory Lymphoma Society.

63 Dr. Muxiang Zhou is funded in part by Dana and Charles Schott Foundation and Ironman for Miracles.

64 Dr. Xiao-Feng Yang is funded in part by the MPD Foundation.

65 Dr. Steven Grant is fully funded by the Peter Burg Memorial Research Fund.

66 Dr. Steven Grant is fully funded by the Peter Burg Memorial Research Fund.

67 Dr. Robert Orlovski is funded in part by the Marge & Lynne accessory Lymphoma Society.

68 Dr. Michael Thirman is funded by The Coleman Foundation.

69 Dr. Benjamin Tycko is funded by the Douglas Reisdorf Research Program.

70 Dr. Yosef Refaeli is funded by the MPS Foundation.
**Medical and Scientific Advisors**

Armand Keating, MD | Chair  
Princess Margaret Hospital

Margaret A. Shipp, MD | Vice Chair  
Dana-Farber Cancer Institute

Irwin Bernstein, MD  
Fred Hutchinson Cancer Research Center

David Bodine, PhD  
National Institutes of Health

Selina Chen-Kiang, PhD  
Weill Medical College of Cornell University

Curt I. Civin, MD  
Johns Hopkins Comprehensive Cancer Center

Brian Druker, MD  
Howard Hughes Medical Institute  
Oregon Health & Science University  
Cancer Institute

Alan M. Gewirtz, MD  
University of Pennsylvania  
School of Medicine

D. Gary Gilliland, MD, PhD  
Harvard Medical School  
Howard Hughes Medical Institute  
Dana-Farber/Harvard Cancer Center  
Harvard Stem Cell Institute

James Griffin, MD  
Dana-Farber Cancer Institute

Judith E. Karp, MD  
Johns Hopkins Comprehensive Cancer Center

Michael W. Long, PhD  
Velocura Therapeutics, Inc.

W. Strazfom May, Jr., MD, PhD  
University of Florida  
Shands Cancer Center

Beverly S. Mitchell, MD  
Stanford University  
Cancer Research Center

Warren S. Pear, MD, PhD  
Abramson Family Cancer Research Institute

Kanti R. Rai, MD  
Long Island Jewish Medical Center

Steven T. Rosen, MD  
Robert H. Lurie Comprehensive Cancer Center

Naomi Rosenberg, PhD  
Tufts University School of Medicine

Nancy Speck, PhD  
Dartmouth Medical School

Guido J. Tricot, MD, PhD  
University of Utah

Cheryl L. Willman, MD  
University of New Mexico  
Cancer Research and Treatment Center

**Professional Education Subcommittee**

Irwin Bernstein, MD | Chair  
Fred Hutchinson Cancer Research Center

Selina Chen-Kiang, PhD  
Weill Medical College of Cornell University

Brian Druker, MD  
Howard Hughes Medical Institute  
Oregon Health & Science University  
Cancer Institute

James Griffin, MD  
Dana-Farber Cancer Institute

Judith E. Karp, MD  
Johns Hopkins Comprehensive Cancer Center

Michael W. Long, PhD  
Velocura Therapeutics, Inc.

Beverly S. Mitchell, MD  
Stanford University  
Cancer Research Center

Margaret A. Shipp, MD  
Dana-Farber Cancer Institute

Guido J. Tricot, MD, PhD  
University of Utah

**Endowment Funds**

Mary & Robert Bronstein Memorial Fund

The Virginia Major Brooks Memorial Endowment Fund

deVillers Endowment Fund

Thomas M. Ford Memorial Fund

GlaxoSmithKline Foundation & GlaxoSmithKline, Inc. Research Fund

Jim Jacobs Leukemia Research Fund

The Rachel Kudish Fund

Jane Elissa/Charlotte Meyers Research Fund

The Rae Endowment Fund

Vrushali Ranadive Fellowship Fund

Reich Endowment Fund

The UFCW Endowment Fund
# Donors

<table>
<thead>
<tr>
<th>$1,000,000 and above</th>
<th>$50,000 – $99,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orakawa Foundation</td>
<td>The Alzhul Foundation/Reichman Memorial Austaca, Inc.</td>
</tr>
<tr>
<td>David &amp; Diann Sant</td>
<td>Hildegard D. Becker Foundation, Inc.</td>
</tr>
<tr>
<td>United Food &amp; Commercial Workers Union (UCFW)</td>
<td>Stephen &amp; Mary Birch Foundation, Inc.</td>
</tr>
<tr>
<td>$500,000 – $999,999</td>
<td>In Memory of Emerson B. Bridges Community Health Charities of Virginia Community Health Charities of Wisconsin Angelo Dilillo and friends</td>
</tr>
<tr>
<td>Name and Organization</td>
<td>Name and Organization</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Greater Milwaukee Foundation, Inc.</td>
<td>Edward L. Milstein</td>
</tr>
<tr>
<td>Milgard Family Foundation</td>
<td>William Miller</td>
</tr>
<tr>
<td>The Mifsud Family Foundation</td>
<td>Mark Mason</td>
</tr>
<tr>
<td>Scott McMullin</td>
<td>Patrick Martin</td>
</tr>
<tr>
<td>Todd McClintock Memorial Research Fund</td>
<td>Thomas Marano</td>
</tr>
<tr>
<td>Laffey McHugh Foundation</td>
<td>Maple Lodge Farms Ltd.</td>
</tr>
<tr>
<td>Casey McGlynn</td>
<td>Thomas Marano</td>
</tr>
<tr>
<td>Linkbrokers Derivatives Corporation</td>
<td>Stephen Leibich</td>
</tr>
<tr>
<td>LMC Ventures</td>
<td>Carl Lindner</td>
</tr>
<tr>
<td>Al Lord</td>
<td>Andrea Procopio</td>
</tr>
<tr>
<td>LS &amp; W Fisher Memorial</td>
<td>Andrea Phipps</td>
</tr>
<tr>
<td>Lukas Lundin</td>
<td>Andrea Pitocco</td>
</tr>
<tr>
<td>Manchester Lions Club</td>
<td>Randy Pitocco</td>
</tr>
<tr>
<td>Jay Mandelbaum</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Samuel P. Mandell Foundation</td>
<td>Royce Pitocco</td>
</tr>
<tr>
<td>Maple Lodge Farms Ltd.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Thomas Marano</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Patrick Martin</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Mark Mason</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Jeffrey Mayer</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Casey McGlynn</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Laffey McHugh Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Todd McClintock Memorial Research Fund</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Scott McMullin</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>David Mitchell</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Monica Ayles, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Monster Mechanical, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Monta Vista High School Octagon Club</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Morgan Stanley</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Barbara and Jim Morrison</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Mother's Day Tea</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>MPD Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Joseph Naggar</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Names Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Neilsen Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>New York State Department of Health</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>in Honor of Senator Marcellino</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Nicholas Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Northwestern Mutual Foundation, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Mayor O'Connor-Memorial Fund</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Yolanda Ogle</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The W. O'Neal Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>P.Drescher Co., Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Shukanta Palta</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Michael Pease</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Pen Air Federal Credit Union</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Phi Gamma Delta Fraternity</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>PhRMA (Pharmaceutical Research &amp; Manufacturers of America)</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Todd Pierce</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Jason Pilas</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Planned Systems International</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Ron &amp; Mary Pott Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Power Corporation of Canada</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Pray Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Andrea Procopio</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Providence Holy Cross Medical Center</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Qualcomm</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Jim Quay Memorial Fund</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Margaret Radin</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Raps for Riches Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Regions Charity Classic Foundation, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Remillard Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>James Resnick</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Rita Rich</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Ritchie Brothers Auctioneers</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Edith Roberts</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Barbara Roth</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Mr. and Mrs. Fred Rowan</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Royals Charities</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>RSM McGladrey</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Paul &amp; Joan Rubschlagier Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Michael Rudman</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Run for the Cause</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Salesforce.com Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Salt River Pima-Maricopa Indian Community</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Sandra Atlas Bass Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Sarver Charitable Trust</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Daniel and Andrea Schriber</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Victor E. and Caroline E. Schutte Foundation – 1959</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Edith M. Schwebekendiek Trust</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Kasem Shafi</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Timothy Shea Memorial</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Shrinkin Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Silicon Valley Community Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Harry Simeone</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Jesse Simon</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Sidney Milton &amp; Leoma Simon Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Kevin Snader</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Judge and Mrs. William Standish</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Steinberg Family Fund, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Peter Stern</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Harry and Jo Ann Stoddard</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Mel Stottlemayre Myetoma Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Steve Strulowitz</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Sugar Lakes Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Frank and Judy Sunberg</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Walter and Louise Sutcliffe Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Susan Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Anne Swift</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Ping Y. Tai Foundation, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Taylor Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>TD Bank Financial Group</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Technicolor</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Tecumseh Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Michael Thomas</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Thrivent Financial for Lutherans Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Edgar A. Thorson Foundation, Inc.</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Lynn and Charles Tighe</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Chris P. Tkalcic Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Alex Trotman Memorial Fund</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>US Bank</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Ernestine P. Vaughan Estate</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Venture Metals</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Vredenburg Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Donald Waite</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Velma Lunt Wallace</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Jim Wallace</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Wal-Mart Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Washington Mutual Bank</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Watkins Family</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Jeffrey Weber</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>West Endowment</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Westjet</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Frederick &amp; Margaret L.Weyerhaeuser Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The WFG Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Wheeler Family Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>The Wilstrom Foundation</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Mark and Sharon Williams</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Timothy Williamson and Teresa Rodriguez Williamson</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Nancy Winkler</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Peter Wright</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Wyner Stokes Charitable Trust</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>John Yantis</td>
<td>Robert Pitocco</td>
</tr>
<tr>
<td>Yaverland Foundation</td>
<td>Robert Pitocco</td>
</tr>
</tbody>
</table>

**Top Campaign Fundraisers**

Individuals who have raised more than $50,000 to support the Society’s mission

- Tim Brackney
- Brad Brody
- Christy and Jay Cashman
- Cara Castellino
- Jim Catena
- Connie Chaney
- Swen Cheung
- Brian Chittenden
- Peter Cronin
- Justin Cutler
- Noah Cutler
- David Dopkin
- Seyhan Duru
- Renee Dusek-Higgins
- Michelle Fried
- Gail Gebhardt
- Alison Gurnitz
- Bob Jackson
- Kim Jones
- Patrick Judge
- Peter Kelly
- Tim Mauro
- Mike Mitchell
- Kevin O’Reilly
- Russ Parker
- Andrea Perry
- Dominic Pitocco
- Laura Rasmussen
- Michele Raeder
- Leslie Rutherford
- Dominic Sergi
- Mike Siegel
- Dr. Melissa Singer
- Amy Smythe
- Pamela Sorensen
- Michael Stack
- Steven Stearns
- Brandon Steven

*National Man & Woman of the Year*
Sponsor Partnerships

Sponsors are institutions or individuals who support a Society event.

$1,000,000 and above
Bristol-Myers Squibb
Celgene Corporation
Genentech, Inc.
Novartis Oncology

$500,000 – $999,999
Cephalon Oncology
Millennium Pharmaceuticals

$100,000 – $499,999
ABC4
American Airlines
Arenen, Inc.
Biogen Idec
Centers for Disease Control and Human Services
Coca-Cola North America
Cystic Fibrosis Foundation

$50,000 – $99,999
American Electric Power (AEP)
American Family
American Heart Association
American Lung Association
American Society for Dermatologic Surgery

$10,000 – $49,999
AstraZeneca
BancFirst
Barnes-Jewish Hospital
Barnes-Jewish Hospital Foundation
Baylor College of Medicine

Genta
Getintegrated
Gil and Billie Thomas
Gil Charitable Foundation
Glamour Magazine
Goldman Sachs
Greater Washington Sports Alliance
Greenberg Traurig, LLP
The Greenbrier Companies
Guaranteed Rate
H&R Block
Harkins Builders, Inc.
Harold Simmons Foundation
Harrah’s Casino
Harris Bank
Hasler, Inc.
Hawthorn Mellody
Hayden Enterprises, Inc.
Hekler-Herman Family Charitable Fund
Henkels and McCoy, Inc.
Highmark
Hochfelder Foundation
Hogan & Hartson
Holt Contracting, Inc.
House of Forgings, Inc.
Hotchkis and Wiley Capital Management
Hy-Vee, Inc.
Human Genome Sciences, Inc.
Hy-Vee, Inc.
IBM
ICAP
IMG
In Memory of Dixie Shadow
Industrial Alliance Pacific Life Insurance Company
InfoCision
International Bank of Commerce
Ironman for Miracles
ITG Investment Technology
Jack Turpin
Jim and Marcus Dougherty
James and Laura Hirshmann
James and Renee Nalls
James L. Eichberg Foundation
James L. DeGeorge & Florence A. Laser Spine Institute
James Nalls
Jay D. Meier Foundation
Jeffries
Jim Koans Automotive Companies
Jim Koans Management Company, Inc.
Jim Triantis
J&M Malas
John and Donna Crean
John and Monika Preston
The John G. Rangos Sr. Charitable Foundation
John Mears Family
Johnson & Johnson
John Stewart
Johnson & Johnson
Jones Geisler, LLP
Joseph Dresser
Journal Communications, Inc.
JP Morgan Chase
Kaiser Permanente
Kathy Lynne Ferguson Zurack
The Katz Foundation
KCE Structural Engineers
Keith and Jeanne Gardner
Ken Gardiner
Kenneth and Benni Newton
Kent Family Charitable Foundation
Ketel One
KETTLER
Keys Rental Management
Kier Corporation
Kitchen & Bath Galleries
Kohl’s No. 428
Knorr
KST Data, Inc.
Lakefront Communications, Inc.
Landmark 24
Landmark Aviation
LandRover Dallas
The Lappin Foundation
LaSalle Bank
Laser Spine Institute
Lawrence J. DeGeorge & Florence A. DeGeorge Charity
Lehman Brothers, Inc.
LEK Consulting
Lighthouse Partners, LLC
Linebarger Goggin, Blair & Sampson
Lockatan Companies
Lunardi’s Supermarket, Inc.
M.G. Rubin
Mabel and Joseph Petuse Foundation
Magellan Development Group, LLC
Major League Baseball Players Association – Players Trust
Marc Wallish
Mark and Carol Spisk
Marriott International, Inc.
Marsh Risk & Insurance Services
Martin and Christine Schuepbach
Marvin and Lorraine Baron
Mayo Clinic
Mayo Foundation
McDonald’s USA, LLC
MCG Capital Corporation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKesson HBOC Foundation, Inc.
MedImmune, Inc.
Memorial Healthcare System
Merk & Co., Inc.
Meredith Corporation Foundation
Merlijn Lynch
Michael McCarthy Foundation
Michael Rudman – Accountancy Corporation
MicroStrategy Fidelity Charitable Gift Fund
Mighty Taco
Mike and Susie Barnett
Mike Tannen
Mizuho Corporate Bank
Modern Amusement
The Moody Foundation
Mona Electric Group
Morgan Franklin
Morgan Stanley
Mount Gay Rum
Multi-Contact USA
MVM, Inc.
Mylan Charitable Foundation
National City Bank
National Cooperative Services Corporation
National Trade Productions CSG
Navarro Discount Pharmacies
Navigant Consulting, Inc.
Neil Barsky
The Neiman Marcus Group
NeoStar, Inc.
New York Mets
NewQuest Properties
NFL Players Association/Players, Inc.
Nicholas Ferrara
Northeastern Metal & Chemicals, Inc.
Norton Healthcare
O’Brien & Ryan, LLP
Odum Brown Limited
Oncology Therapeutics Network
ONCORE Concrete
Onyx Equities
Oracle Corporation
Orlando Regional Healthcare System
OTJ Architects
Pfizer, Inc.
Powers & Pipetters Service Technicians, Local Union 72
PNC Bank
Pola Ralph Lauren Foundation
Powell Goldstein, LLP
Powell Industries
PPG
Prairie Farms
Price Modern
Pravivit
Providence Health System
Puylup Tribe of Indians
Quantum Imaging & Therapeutic Associates, Inc.
Quest Diagnostics
Quicken Loans
Rabobank International
Radio One
Rags for Riches Foundation
Raytheon
Regency Commercial Construction
Regional Consultants in Hematology & Oncology
Relativity Media
Resources Global Professionals
Res Electric, Inc. & Technologies
Rhoda & David Chase Family Foundation
Richard and Julie Healey
Richard Schechter
Ritchie Brothers Auctioneers
Robert and Mary Jane Engman
Robert L. Johnson
Robert M. Rogers Foundation
Robert Michael Educational Institute, LLC
Rockey Mountain Blood & Marrow Transplant Program
Rosenthal Properties, LLC
Royal Bank of Scotland
Royal Marine Insurance Group
Royal Oak Ford
Royal Paper Products, Inc.
Royal Marine Insurance Group
Royal Oak Ford
Ruth Robinson
RR Donnelley
RWB Specialties, Inc.
Sallie Mae
Sam Molinaro
Samuel J. & Connie M. Frankino Charitable Foundation
SanDisk Corporation Fund
Santos, Postal & Company, PC
SAP
SAP Global Marketing
Satterfield & Pontikes
SAP Global Marketing
Santos, Postal & Company, PC
SAP
SAP Global Marketing
Satterfield & Pontikes
Saska Capital
Scott and Kathi Shuford
Scott Health & Safety
The Scotts Company
Sears Manufacturing Company
The Leukemia & Lymphoma Society
Sponsor Partnerships (continued)

Promotion Partnerships

Promotions are individuals or institutions that organize an event and donate proceeds to the Society.

$1,000,000 and above
KGO Newstalk AM 810

$500,000 – $999,999
The Beer Store

$100,000 – $499,999
American Bicycle Association
Big Steaks Management, LLC

Option One Mortgage Company
Parents Against Leukemia
Spin for the Cure
Swing for a Cure
Wilson Sonsini Goodrich & Rosati

$10,000 – $49,999

94.7 The Globe

$50,000 – $99,999

EnCana Oil & Gas, Inc.
Drive for a Cure

$100,000 and above

Wilson Sonsini Goodrich & Rosati
LLB Golf Tournament,
Local Operating Engineers No. 3

$10,000 – $49,999

Drive for a Cure

$50,000 – $99,999

Gas America Charitable Foundation

$100,000 and above

Frightland, LLC

$10,000 – $49,999

Amesha Centers

$50,000 – $99,999

Garden Fresh Charities

Sponsor Partnerships

Sedano’s Supermarkets
Sevelli Family of Dealerships
Sharp Electronics Corporation
Sidley Austin, LLP
Siemens Corporation
Simmons Cooper, LLC
Skybridge Capital
Slayton Search Partners
Smith Barney
Sodexo Corporate Services
Sony DADC
Southern California Gas Company
SouthWest Bank
Spectrum, Inc. General Contracting
SportsNet New York
Sprint
St. Joseph’s/Candler
St. Luke’s Mountain States Tumor Institute
St. Vincent de Paul Foundation, Inc.
Stanek Constructors, Inc.
Stavros Shapiro
The Staubach Company
Stanley Shapiro
Stanek Constructors, Inc.

Summit Chalet Properties, LLC
Summers & Johnson, PC
Sunburst Hospitality Corporation
Sunsail
Sunesis Pharmaceutical
Sunrise Hospitality Corporation
Summit Chalet Properties, LLC
SouthWest Bank
Southern California Gas Company
Sony DADC
Southern California Gas Company
SouthWest Bank
Spectrum, Inc. General Contracting
SportsNet New York
Sprint
St. Joseph’s/Candler
St. Luke’s Mountain States Tumor Institute
St. Vincent de Paul Foundation, Inc.
Stanek Constructors, Inc.
Stanley Shapiro
The Staubach Company
Stein, Kessler, Goldstein & Fox, PLLC
Stop & Shop
StrongSuit Consulting/Stephco
Structure Tone, Inc.
Summers & Johnson, PC
Sunburst Hospitality Corporation
Sunesis Pharmaceutical
Sunsail
Suzy Minkoff
TD Banknorth, N.A.
TD Securities (USA), LLC
Tetus
Tenet Choices, Inc.
Tesoro Refining & Marketing Company
Thelen Reed Brown Rayskin & Steiner, LLP
Thomas Weisel Partners, LLC
Thompson Habib Dension
Thrivent Financial for Lutherans Foundation Total
Tim and Maura Castello
Timberlake Homes
Tom Luglio
Tony and Una Giachinta
Toyota of Bowie
Tri Total Media
Tricon Construction, Inc.
Trinity Lutheran Church
Trinity Select III – Abate Seafood & Dingbats Restaurants
Truland Systems Corporation
Turner Healthcare
Turner Interiors
UBS Investment Bank
United States Steel
University Hospitals
University of Florida Shands Cancer Center
University of Kentucky
UPMC Cancer Centers
Virginia Oncology Associates
Vistar Corporation
W.E. Bowers
Wachusett Dealer Services
Wachusett Insurance Services
Wachusett Securities
Wachusett Wealth Management
Wakefield Capital, LLC
Washington Area Chrysler-Jeep-Dodge Dealers
Washington Consulting, Inc.
an Alion Company
Washington Convention Center
Washington Gas
The Washington Redskins
Waste Management
Watson Wyatt Worldwide
WebMD Health Foundation, Inc.
Wells Fargo
Wesley and Anne Poulson
West Marine
White Oak Operating Co., LLC
William Ashman
William Hawthorne
Williams & Connolly LLP
Wilmer Cutler Pickering Hale and Dorr, LLP
Winston Partners Group, LLC
WWB-TCV, Channel 4
The Woodlands Operating Company
WTSS, Star 102.5 FM
Wyeth Pharmaceuticals
XO Communications

Option One Mortgage Company
Parents Against Leukemia
Spin for the Cure
Swing for a Cure
Wilson Sonsini Goodrich & Rosati

$10,000 – $49,999

94.7 The Globe

$50,000 – $99,999

EnCana Oil & Gas, Inc.
Drive for a Cure

$100,000 and above

Wilson Sonsini Goodrich & Rosati
LLB Golf Tournament,
Local Operating Engineers No. 3

$10,000 – $49,999

Drive for a Cure

$50,000 – $99,999

Gas America Charitable Foundation

$100,000 and above

Frightland, LLC

Josh Hamilton
Kaielin Family Captain’s Cup
Knorr
List Innovations Solutions
LLB Golf Tournament,
Local Operating Engineers No. 3
Lowndes, Drassick, Doster,
Kantor & Reed, PA
Lucidity Consulting Group
Mandy Atwall
MAPPING
Mark Anthony Brands, Inc.
Mark Grace Foundation
Media/Professional Insurance
Merck Development, Inc.
MetLife
Meyers, Harrison & Pia, LLC
Miele Lane
National Pest Control Association
Peter and Shelley Friesen
Premier Foods
Production Management Group
Ratops
Rob’s Automotive and Collision Center
San Par Golf Tournament
Should Be.
Siemens
Soroptimist International of the Langleys
St. Martin Luther Church
STANY Foundation, Inc.
Steve Gorry
Steve Turk Memorial Classic
Stinson Morrison Hecker, LLP
Susan and Michael Schuldes
TeamFootWorks
Waddell & Reed
Waddell & Reed Kansas City Marathon
WASH FM
Washington Business Journal
Washingtonian
Washingtonian
Wechsler/Marsico Associates
Wendy’s of Michigan
White Castle
Wisconsin Public Service
Legacy Circle honors those who have included the Society in an estate plan or bequeathed a gift over $50,000.

Lynn Aaronson  
Richard Abel  
Linda Abemathy  
Kathleen O’Meara Abramson  
Maria Castellanos-Acevedo  
Chris Adar  
Agostina Alagna  
Hugh Albara  
Chico and Kay Alcantar  
Lisa Jane Alexander  
Peter Alexos  
Bruce and Fay Allen  
Ralph Allocco  
Bruce and Fay Allen  
Angela Alagna  
Chris Adair  
Maria Castellanos-Acevedo  
Kathleen O’Meara Abramson  
Linda Abernath  
Richard Abel  
Lynn Aaronson  
bequeathed a gift over $50,000. 

The Legacy Circle
The Legacy Circle (continued)

Jeanne Burns-Handel
Gay Nell Hall
Mr. and Mrs. Ken Haller
John Hallissey
John and Yvette Haluck
Lila Hamilton
Leon Hammeman
Florence Haney
Joan Haratani
Nina Harding, Esq.
Keith P. and Linda Herrera
Alice Hatch
Pat Hauer
Robin Hayes
Kathleen Hays
Jean Hegland
Donald P. Heim
William Heinz
Debbie Helverson
Tom and Wendy Henry
Julie Henderson
Karen and Tony Hermer
Lauren Hertel
Lynda Hess
Mr. and Mrs. Larry Hexter
Dr. Saul Highman
Joan Haratani
Hiram D. Hoch
Joan Hill
Catherine E. Hildreth
Anna Hildreth
Dr. and Mrs. Nathan Katz
Harvey Kaslow
Dr. and Mrs. Nathan Katz
Steven and Patricia Kaufmann
Patricia Kay
Mr. and Mrs. Christopher J. Kearns
Frances Keating
Michael E. Keefe
Vicki Kelcher
Sally K. Blume-Kelly
Sydney and Isabel Kemper
Michael Kerper
James Kimball
Dr. Vincu L. Walton-Kimmel
Annabelle King, MD
T. Corey Kipp
Marvin Kirchner
Monica Klapper
Michael and Jackie Kluk, Jr.
Jerry and Faylene Kluever
Susan Kobrel
Ester Koch
Karl Koepeke
Jeff and Teresa Kopietz
Charles Kapler *
Rich Kostum
Mark and Christine Kraemer
Carmella Kramer
Marian Kramer
Lillian Kraus Trust *
Leslie Elliot Krause, Esq.
Dixie Kreider
Marja Kremikow
Scott and Megan Krizek
Gail Kromer
Mr. and Mrs. Greg Kuhl
Scott Kuster
Jana LaCock
John Lamb, Jr.
Julie Landau
Herbert Landek
Dr. Luvelle Lang
Alan P. Laskin
Larry Laughlin
Janet LaVerre *
Mr. and Mrs. Jeffrey Lawrence
William S. Lear
David Lee
Diana Lynn Lee
Gail M. Lee
Joseph Louis Lee
Kelli Leffingwell
Lon Lenave
Alayna Lennon
Martha Lennie
Robert Lew
Paul L. Lewis
Robert Lindsey
Bryan Lintong
Debora Lingquist
Jennifer Lisicke
Harvey and Linda Litofsky
Geoffrey Lombard
Dennis and Leslie Ann Lorenz
Bruce Lavin
Joseph Ludwik
Laurence Luke
Franz and Leslie Luxen
Mr. and Mrs. F.F. Michael Lynch
Eric and Becky Mahlum
Georgia Davids Malone
Dominic Manturo
Stanley M. Marks, MD
Gary Martin
William Martin
Mark E. Mason
Greg and Mary Matz
Joan Maves
Robert and Marmee Maylone
Willie McCann *
Dorothy McCann
John and Patty McDonald
Thomas McDonald
Manlyn McDonnald
Sylvia McGovern
Carolyn E. McKown
Susan Meloddon
Clayton J. and Gladys M. McPhail
Anthony McPherson
Rita Meek, MD
Rhonda Meeks
Timothy and Susan Metzer
Michelle Michalik
Lisa A. Mihalik
James Miller
Paul Hart Miller
Tammanie Miligan
Terri Mistead
Suzy Minkoff
Eileen Minnick
Shelly Mirabito
Joshua Mitchell, MD
Ted Mocian
Evelyn Wenzel-Modorzewski
Lori Mody
Mason Moise
Tammy Molay
Karen Mongiello
Dennis F. Moore, MD
Robert and Valerie Moore
William Moore
Joanne A. Moran
Mr. and Mrs. Thaddee F. Moreau
Bonnie J. Moreno
Sean Moriarty
Caroline Morris
Dennis Morris
Hope Morrison
Marcie Morrison
James Morton
Stephen and Karen Moss
Bob and Bekah Moyle
Frank Mungo
Suzanne J. Muntzing
Oscar M. and Ruth M. Muskapf
Virginia Musser
Rodman N. Myers
Virginia Myers *
Robert J. Myers
Ali Nadim
Paul Nagle
James T. Nangle
Paul and Carol Ann Neiman
Richard and Joyce Nelson
Hon. Robert H. Newman
Tracy Newman
Robert C. Niles
Lisa Nir
Regina Nizzoli
Edward Nofler III
Dwight Norris
Jason North
Coral Norton
Richard F. Nourie
Jeanne Null
Joseph Obegi
Dorothy Obert
Jerry and Carolyn O’Hara
Margaret Olmazou
Edward D. O’Malley
George and Alicia Omiros
Rita Oppenheimer
Hedi Ortgren
Ladd Orzech
Harry O’Toole
Mary J. Oyer
Jacqueline Palmenberg
Brian and Beth Palmer
Mr. and Mrs. Paul Paluch
Billie Sue Parris
The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2007, and the related consolidated statements of activities, cash flows, and functional expenses for the year then ended. These consolidated financial statements are the responsibility of the Society's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society's 2006 consolidated financial statements and, in our report dated October 24, 2006, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2007, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

KPMG LLP

October 24, 2007
New York, NY
## Consolidated Statement of Financial Position

The Leukemia & Lymphoma Society, Inc. | June 30, 2007  
(with comparative amounts at June 30, 2006) (in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 46,949</td>
<td>$ 49,248</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,686</td>
<td>649</td>
</tr>
<tr>
<td>Legacies and contributions receivable (note 2)</td>
<td>4,321</td>
<td>6,129</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>4,711</td>
<td>5,062</td>
</tr>
<tr>
<td>Investments, at fair value (note 3)</td>
<td>145,717</td>
<td>108,693</td>
</tr>
<tr>
<td>Fixed assets, less accumulated depreciation and amortization of $10,435 and $8,857</td>
<td>4,656</td>
<td>4,249</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$ 208,040</td>
<td>$ 174,030</td>
</tr>
</tbody>
</table>

| **Liabilities and Net Assets** |       |            |
| **Liabilities:**              |       |            |
| Accounts payable and accrued expenses | $ 18,339 | $ 18,365 |
| Deferred revenue              | 15,258 | 12,803    |
| Grants payable (note 4)       | 77,245 | 70,000    |
| **Total liabilities**         | 110,842 | 101,168   |

| **Net assets:**               |       |            |
| Unrestricted                  | 85,691 | 64,628    |
| Temporarily restricted (note 7) | 8,634  | 5,403     |
| Permanently restricted (note 7)| 2,873  | 2,831     |
| **Total net assets**          | 97,198 | 72,862    |

| **Total liabilities and net assets** | $ 208,040 | $ 174,030 |

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Activities

**The Leukemia & Lymphoma Society, Inc. | Year ended June 30, 2007**  
(with summarized totals for the year ended June 30, 2006) (in thousands)

### Revenue

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$274,055</td>
<td>$17,979</td>
<td>2</td>
<td>$292,036</td>
<td>$265,596</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(42,455)</td>
<td>-</td>
<td>-</td>
<td>(42,455)</td>
<td>(38,536)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>231,600</td>
<td>17,979</td>
<td>2</td>
<td>249,581</td>
<td>227,040</td>
</tr>
<tr>
<td>Legacies</td>
<td>4,810</td>
<td>127</td>
<td>-</td>
<td>4,937</td>
<td>2,745</td>
</tr>
<tr>
<td>Donated services (note 1)</td>
<td>5,051</td>
<td>-</td>
<td>-</td>
<td>5,051</td>
<td>4,896</td>
</tr>
<tr>
<td>Net interest and dividend income (note 3)</td>
<td>6,140</td>
<td>111</td>
<td>-</td>
<td>6,251</td>
<td>3,788</td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>7,367</td>
<td>71</td>
<td>40</td>
<td>7,478</td>
<td>1,538</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>1,304</td>
<td>-</td>
<td>-</td>
<td>1,304</td>
<td>1,387</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>15,057</td>
<td>(15,057)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total revenue</td>
<td>271,329</td>
<td>3,231</td>
<td>42</td>
<td>274,602</td>
<td>241,394</td>
</tr>
</tbody>
</table>

### Expenses (note 8)

#### Program Services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>69,269</td>
<td>-</td>
<td>-</td>
<td>69,269</td>
<td>63,570</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>66,844</td>
<td>-</td>
<td>-</td>
<td>66,844</td>
<td>62,912</td>
</tr>
<tr>
<td>Public health education</td>
<td>38,379</td>
<td>-</td>
<td>-</td>
<td>38,379</td>
<td>35,078</td>
</tr>
<tr>
<td>Professional education</td>
<td>7,931</td>
<td>-</td>
<td>-</td>
<td>7,931</td>
<td>8,020</td>
</tr>
<tr>
<td>Total program services</td>
<td>182,423</td>
<td>-</td>
<td>-</td>
<td>182,423</td>
<td>169,580</td>
</tr>
</tbody>
</table>

#### Supporting Services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>23,663</td>
<td>-</td>
<td>-</td>
<td>23,663</td>
<td>23,017</td>
</tr>
<tr>
<td>Fund raising</td>
<td>44,180</td>
<td>-</td>
<td>-</td>
<td>44,180</td>
<td>42,667</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>67,843</td>
<td>-</td>
<td>-</td>
<td>67,843</td>
<td>65,684</td>
</tr>
</tbody>
</table>

### Change in net assets

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total expenses</td>
<td>$250,266</td>
<td>$235,264</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>24,336</td>
<td>6,130</td>
</tr>
</tbody>
</table>

### Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>64,628</td>
<td>66,732</td>
</tr>
<tr>
<td>End of year</td>
<td>$85,691</td>
<td>$72,862</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc.  
Year ended June 30, 2007  
(with comparative amounts for the year ended June 30, 2006)  
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$24,336</td>
<td>$6,130</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>(7,478)</td>
<td>(1,538)</td>
</tr>
<tr>
<td>Permanently restricted revenue collected</td>
<td>(2)</td>
<td>(112)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>1,578</td>
<td>1,246</td>
</tr>
<tr>
<td><strong>Changes in operating assets and liabilities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(1,037)</td>
<td>23</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>1,808</td>
<td>(1,103)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>351</td>
<td>(816)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(26)</td>
<td>698</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>2,455</td>
<td>2,048</td>
</tr>
<tr>
<td>Grants payable</td>
<td>7,245</td>
<td>13,226</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>$29,230</td>
<td>$19,802</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities:** |            |            |
| Purchases of fixed assets       | (1,985)    | (1,397)    |
| Purchases of investments        | (160,144)  | (136,482)  |
| Sales of investments            | 130,598    | 112,960    |
| **Net cash used in investing activities** | (31,531)   | (24,919)   |

| **Cash flows from financing activities:** |            |            |
| Permanently restricted contributions collected | 2          | 112        |
| **Net cash provided by financing activities** | 2          | 112        |
| **Net decrease in cash and cash equivalents** | (2,299)    | (5,005)    |
| **Cash and cash equivalents at beginning of year** | 49,248     | 54,253     |
| **Cash and cash equivalents at end of year** | $46,949    | $49,248    |

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. | Year ended June 30, 2007  
(with comparative totals for the year ended June 30, 2006) (in thousands)

<table>
<thead>
<tr>
<th></th>
<th>Program Services Expenses</th>
<th>Supporting Services Expenses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research</td>
<td>Patient and Community Service</td>
</tr>
<tr>
<td>Awards and grants</td>
<td>$ 66,540</td>
<td>$ –</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>–</td>
<td>6,003</td>
</tr>
<tr>
<td>Donated services</td>
<td>724</td>
<td>4,327</td>
</tr>
<tr>
<td>Salaries</td>
<td>802</td>
<td>28,156</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 5)</td>
<td>128</td>
<td>6,403</td>
</tr>
<tr>
<td>Occupancy</td>
<td>21</td>
<td>3,091</td>
</tr>
<tr>
<td>Insurance</td>
<td>8</td>
<td>247</td>
</tr>
<tr>
<td>Telephone</td>
<td>23</td>
<td>2,256</td>
</tr>
<tr>
<td>Travel</td>
<td>56</td>
<td>1,210</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>156</td>
<td>2,954</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>10</td>
<td>751</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>50</td>
<td>1,012</td>
</tr>
<tr>
<td>Meetings</td>
<td>222</td>
<td>2,660</td>
</tr>
<tr>
<td>Professional fees</td>
<td>507</td>
<td>6,863</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>5</td>
<td>535</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>17</td>
<td>576</td>
</tr>
<tr>
<td>Total expenses</td>
<td>$ 69,269</td>
<td>$ 66,844</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
1. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (the "Society") is an international not-for-profit health agency dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin's disease and myeloma and improving the quality of life of patients and their families. The Society's principal activities include: awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood cancer information made to the Society's Information Resource Center; and disseminating educational information about blood cancers in the form of publications, internet sites, conference calls and symposia sponsorship for both the medical community and the general public.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Society, which encompasses the Home Office of the Society and its sixty four chapters, The Leukemia & Lymphoma Society of Canada, Inc. ("LLSC"), and the Society's not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc. and The Leukemia & Lymphoma Society Research Foundation. All significant inter-company and intra-Society accounts and transactions have been eliminated in consolidation.

Tax-Exempt Status
The Society qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since the Society is publicly-supported, contributions to the Society qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is therefore not subject to income taxes if certain disbursement requirements are met.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to the Society, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of the Board of Directors, for the Society to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period or purpose, as well as amounts relating to term endowment or deferred giving arrangements in which the funds must be maintained intact over the lifetimes of the donors.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met.

Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services
The Society has determined that certain of the donated services it receives meet the criteria for recognition in the financial statements. Specifically, the donated services of family support group facilitators and research grant reviewers have been valued and are reported as both revenue and expense.

Cash Equivalents
Cash equivalents consist of short-term investments with a maturity of three months or less from date of purchase, except for amounts held for long-term purposes reported as investments.

Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, if purchased, or at fair value at date of donation, if contributed, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter.

Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires the Society's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Summarized Financial Information
The financial statements are presented with 2006 summarized or comparative information. With respect to the statement of activities, such prior year information is not presented by net asset class and, in the statement of functional expenses, 2006 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with the Society's 2006 consolidated financial statements from which the summarized information was derived. Certain reclassifications have been made to the 2006 comparative information to conform to the current year presentation.
2. Legacies and Contributions Receivable

The Society's legacies and contributions receivable at June 30, 2007 and 2006 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$3,197</td>
<td>$5,028</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>622</td>
<td>1,169</td>
</tr>
<tr>
<td>After 5 years</td>
<td>778</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4,597</strong></td>
<td><strong>6,197</strong></td>
</tr>
</tbody>
</table>

Less discount to present value (discount rate – 5%)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(276)</td>
<td>(68)</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4,321</strong></td>
<td><strong>6,129</strong></td>
</tr>
</tbody>
</table>

3. Investments

The following is a summary of investments at June 30, 2007 and 2006 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost or</td>
<td>Cost or</td>
</tr>
<tr>
<td></td>
<td>Donated</td>
<td>Donated</td>
</tr>
<tr>
<td></td>
<td>Value</td>
<td>Value</td>
</tr>
<tr>
<td>Money market funds</td>
<td>$1,419</td>
<td>$1,419</td>
</tr>
<tr>
<td></td>
<td>$1,419</td>
<td>$1,419</td>
</tr>
<tr>
<td></td>
<td>$192</td>
<td>$192</td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>42,744</td>
<td>42,323</td>
</tr>
<tr>
<td></td>
<td>38,958</td>
<td>38,127</td>
</tr>
<tr>
<td>Common stocks and mutual funds</td>
<td>29,072</td>
<td>35,395</td>
</tr>
<tr>
<td></td>
<td>27,124</td>
<td>31,927</td>
</tr>
<tr>
<td>Government obligations</td>
<td>47,009</td>
<td>47,186</td>
</tr>
<tr>
<td></td>
<td>24,137</td>
<td>24,112</td>
</tr>
<tr>
<td>Other</td>
<td>17,309</td>
<td>19,394</td>
</tr>
<tr>
<td></td>
<td>6,312</td>
<td>7,335</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$137,953</td>
<td>$145,717</td>
</tr>
<tr>
<td></td>
<td>$104,507</td>
<td>$108,693</td>
</tr>
</tbody>
</table>

Debt and equity securities are recorded at fair value as determined by quoted market prices. Mutual funds are recorded at fair value using published unit values. Other investments at June 30, 2007, consist principally of limited partnerships, the underlying holdings of which are principally marketable securities. Investment expenses of $436,000 and $335,000 have been netted against interest and dividend income for the years ended June 30, 2007 and 2006, respectively.

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society's Board of Directors. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society's Board of Directors. In addition to unconditional grants payable of $77,245,000 at June 30, 2007, the Society has grant commitments of $106,000,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Pension Plan

The Society has a noncontributory, defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expense under this plan aggregated $3,133,000 and $3,020,000 for the years ended June 30, 2007 and 2006, respectively.

On July 1, 2006, the Society adopted a 457 Deferred Compensation Plan (the “457 Plan”), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Section 457. Expenses under this plan approximated $194,000 for the year ended June 30, 2007. The assets and liabilities of this plan amounted to approximately $285,000 and are included in investments and accounts payable in the accompanying 2007 statement of financial position.

6. Lease Commitments

The leases for premises which the Society's Home Office and chapters occupy expire on various dates through December 31, 2012 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities.

The approximate minimum future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>$6,827</td>
<td>$6,284</td>
<td>$5,491</td>
<td>$3,146</td>
<td>$1,362</td>
<td>$209</td>
<td>$23,319</td>
</tr>
</tbody>
</table>

7. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2007 and 2006 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Temporarily Restricted</td>
<td>Permanently Restricted</td>
</tr>
<tr>
<td>Research</td>
<td>$1,907</td>
<td>$2,825</td>
</tr>
<tr>
<td>Patient service</td>
<td>6,662</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>65</td>
<td>48</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$8,634</td>
<td>$2,873</td>
</tr>
</tbody>
</table>

8. Joint Costs Allocation

In 2007 and 2006, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2007</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$14,069</td>
<td>$13,661</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,038</td>
<td>1,051</td>
</tr>
<tr>
<td>Public health education</td>
<td>11,652</td>
<td>11,067</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$26,759</td>
<td>$25,779</td>
</tr>
<tr>
<td>Position</td>
<td>Name</td>
<td>Company/University</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Chair of the Board</td>
<td>David Frantze</td>
<td>Stinson Morrison Hecker, LLP</td>
</tr>
<tr>
<td>Vice Chair for Medical and Scientific Affairs</td>
<td>Armand Keating, MD</td>
<td>Princess Margaret Hospital Toronto, Ontario, Canada</td>
</tr>
<tr>
<td>Vice Chair for Field Relations</td>
<td>Paul J. Cienki</td>
<td>Honeywell</td>
</tr>
<tr>
<td>Vice Chair for Patient Services</td>
<td>Marie Lauria, MSW</td>
<td>Chapel Hill, NC</td>
</tr>
<tr>
<td>Vice Chair for Resource Development</td>
<td>Margaret H. Anderson</td>
<td>Anderson, Bryant, Lasky &amp; Winslow, PSC</td>
</tr>
<tr>
<td>Secretary/Treasurer</td>
<td>Thomas L. Fitzpatrick</td>
<td>Saint Gobain Corporation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board of Directors</td>
<td>Alexandra Mayes Birnbaum</td>
<td>Peartree Communications, Inc.</td>
</tr>
<tr>
<td></td>
<td>Robert A. “Spider” Cantley</td>
<td>Twain Harte, CA</td>
</tr>
<tr>
<td></td>
<td>Scott Carroll</td>
<td>Voyrs, Sater, Seymour and Peas, LLP</td>
</tr>
<tr>
<td></td>
<td>Michael Copley</td>
<td>LMC Ventures, LLC</td>
</tr>
<tr>
<td></td>
<td>Timothy Durst</td>
<td>Baker Batts, LLP</td>
</tr>
<tr>
<td></td>
<td>Paul N. Frimmer</td>
<td>Irell &amp; Manella, LLP</td>
</tr>
<tr>
<td></td>
<td>John A. Geoghegan</td>
<td>Gelert &amp; Klein, PC</td>
</tr>
<tr>
<td></td>
<td>Alan M. Gewirtz, MD</td>
<td>University of Pennsylvania School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Carter K. D. Guice, Jr.</td>
<td>Assistant U.S. Attorney</td>
</tr>
<tr>
<td></td>
<td>Steven L. Hooker</td>
<td>The Regence Group</td>
</tr>
<tr>
<td></td>
<td>Lynn C. Hoover</td>
<td>Stinson Morrison Hecker, LLP</td>
</tr>
<tr>
<td></td>
<td>Thomas F. Hunter</td>
<td>Stimulys Performance Marketing</td>
</tr>
<tr>
<td></td>
<td>Charles F. Inglefield</td>
<td>Bay Village, OH</td>
</tr>
<tr>
<td></td>
<td>John M. Kamins</td>
<td>Honigman Miller Schwartz and Cohn</td>
</tr>
<tr>
<td></td>
<td>Leslie Elliot Krause, Esq.</td>
<td>Krause &amp; Mauer, LLP</td>
</tr>
<tr>
<td></td>
<td>Michael W. Long, PhD</td>
<td>Velcura Therapeutics, Inc</td>
</tr>
<tr>
<td></td>
<td>Dennis F. Marco</td>
<td>North Haledon, NJ</td>
</tr>
<tr>
<td></td>
<td>W. Straford May, Jr., MD, PhD</td>
<td>University of Florida Shands Cancer Center</td>
</tr>
<tr>
<td></td>
<td>James McKinnis</td>
<td>Rapp Collins Worldwide</td>
</tr>
<tr>
<td></td>
<td>Rodman N. Myers</td>
<td>Honigman Miller Schwartz and Cohn</td>
</tr>
<tr>
<td></td>
<td>Jason North</td>
<td>JSN Consulting</td>
</tr>
<tr>
<td></td>
<td>Frederic C. Parvey</td>
<td>Fidelity National Financial</td>
</tr>
<tr>
<td></td>
<td>Naomi Rosenberg, PhD</td>
<td>Tufts University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Kevin R. Ryan</td>
<td>Yampolsky, Mandeloff, Silver, Ryan</td>
</tr>
<tr>
<td></td>
<td>Frank T. Short</td>
<td>Short Strategy Group, Inc</td>
</tr>
<tr>
<td></td>
<td>Norbert J. Sieber</td>
<td>NJS Consultants</td>
</tr>
<tr>
<td></td>
<td>Jay L. Silver</td>
<td>Sugar Land, TX</td>
</tr>
<tr>
<td></td>
<td>Thomas R. Snyder</td>
<td>Nashville Bank and Trust</td>
</tr>
<tr>
<td></td>
<td>James J. Stephanak</td>
<td>The Kalamazoo Gazette</td>
</tr>
<tr>
<td></td>
<td>William M. Ward, Jr.</td>
<td>Presbyterian Manors of Mid-America</td>
</tr>
<tr>
<td></td>
<td>Charles Wiener</td>
<td>Bernard L. Madoff Investment</td>
</tr>
<tr>
<td></td>
<td>Michele Wong</td>
<td>Synergex</td>
</tr>
</tbody>
</table>

The Leukemia & Lymphoma Society
Officers
Harry J. Pearce | President
Of Counsel
Bowman and Brooke
David Frantze | Vice President
Stinson Morrison Hecker, LLP
Armand Keating, MD | Medical Vice President
Princess Margaret Hospital
Dwayne Howell | Secretary-Treasurer
President and Chief Executive Officer
The Leukemia & Lymphoma Society

Members
Alexandra Mayes Birnbaum
Peartree Communications, Inc.
Tom Bertelsen
Dominican Sisters of San Rafael
Andrew Madoff
Bernard L. Madoff Investment Securities
Dee Sanfilippo
Property Management Company
Doug Smith
Value Creation Partners
Scott Zeilinger
Kadma Partners, LLC

Medical Advisory Board
James R. Berenson, MD
Institute for Myeloma & Bone Cancer Research
Brian Druker, MD
Howard Hughes Medical Institute
Oregon Health & Science University Cancer Institute
Margaret A. Shipp, MD
Dana-Farber Cancer Institute

Dwayne Howell
President and Chief Executive Officer
Laurence W. Hausner
Chief Operating Officer
John E. Walter
Executive Vice President Strategic Alliances and New Business Development

Field Management
Paul Weiss
Senior Vice President
Field Management
Leslie Chambers
Senior Vice President
Field Management

Finance, Administration
Jimmy Nangle
Senior Vice President
Chief Financial Officer

Research and Medical Programs
Marshall A. Lichtman, MD
Executive Vice President
Research & Medical Programs
Louis DeGennaro, PhD
Senior Vice President
Research Administration

Revenue Development
Greg Elfers
Senior Vice President
Revenue Development

The Leukemia & Lymphoma Society of Canada
Rudy Puts
Chief Executive Officer

Research and Medical Programs
Marshall A. Lichtman, MD
Executive Vice President
Research & Medical Programs
Louis DeGennaro, PhD
Senior Vice President
Research Administration

Revenue Development
Greg Elfers
Senior Vice President
Revenue Development

The Leukemia & Lymphoma Society of Canada
Rudy Puts
Chief Executive Officer

Government and Legislative Affairs
George Dahlman
Senior Vice President
Public Policy

Information Technology
Jon R. Lowell
Senior Vice President
Chief Technology Officer

Marketing Communications
Nancy Klein
Senior Vice President
Marketing Communications

Patient Services
Robin Kornhaber, MSW
Senior Vice President
Patient Services
The Society is a nonprofit organization that relies on the generosity of individual, foundation and corporate contributions to advance its mission.